Inventor · disambiguated record
Dennis Buckley
Also filed as: BUCKLEY DENNIS · BUCKLEY DENNIS L
28 granted patents·11 pending applications·491 citations·filing 2013–2024
97Inventor score
Top patents by PatentIndex Score
39 records- 0198US10464925B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 5, 2019·36 cites·16 claims
- 0298US10125114B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2017·Granted Nov 13, 2018·57 cites·20 claims
- 0398US9821068B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2016·Granted Nov 21, 2017·71 cites·117 claims
- 0498US9770512B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2016·Granted Sep 26, 2017·63 cites·42 claims
- 0598US9750816B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2016·Granted Sep 5, 2017·62 cites·56 claims
- 0698US9694084B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 4, 2017·76 cites·84 claims
- 0797US10849980B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2019·Granted Dec 1, 2020·16 cites·45 claims
- 0897US10669253B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 2, 2020·17 cites·19 claims
- 0996US11583586B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2020·Granted Feb 21, 2023·3 cites·21 claims
- 1092US10239888B2Targeted protein degradation using a mutant E3 ubiquitin ligaseDANA FARBER CANCER INST INC·Filed 2018·Granted Mar 26, 2019·18 cites·2 claims
- 1191US11311609B2Regulating chimeric antigen receptorsDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 26, 2022·6 cites·29 claims
- 1291US10730862B2Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligaseUNIV YALE·Filed 2013·Granted Aug 4, 2020·15 cites·14 claims
- 1391US9695172B2Diazepane derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Jul 4, 2017·13 cites·74 claims
- 1490US11059801B2Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2020·Granted Jul 13, 2021·2 cites·22 claims
- 1589US10980808B2Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathiesCHILDRENS MEDICAL CT CORP·Filed 2017·Granted Apr 20, 2021·4 cites·9 claims
- 1688US10308653B2Diazepane derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Jun 4, 2019·8 cites·24 claims
- 1786US11944625B2Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathiesCHILDRENS MEDICAL CT CORP·Filed 2021·Granted Apr 2, 2024·1 cites·17 claims
- 1886US11046954B2Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 29, 2021·2 cites·17 claims
- 1986US10899768B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Jan 26, 2021·3 cites·19 claims
- 2086US9951074B2Dihydropteridinone derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 24, 2018·6 cites·19 claims
- 2185US11285218B2Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Mar 29, 2022·5 cites·4 claims
- 2284US11578075B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2020·Granted Feb 14, 2023·1 cites·17 claims
- 2384US10793571B2Uses of diazepane derivativesDANA FARBER CANCER INST INC·Filed 2015·Granted Oct 6, 2020·2 cites·20 claims
- 2480US11306105B2Cyano thienotriazolodiazepines and uses thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Apr 19, 2022·3 cites·28 claims
- 2574US2022135967A1Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 2674US2023131952A1Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 2774US2024317729A1Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin LigaseUNIV YALE·Filed 2024·Application pending·0 cites
- 2871US2018085465A1Methods to induce targeted protein degradation through bifunctional moleculesDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 2971US2021301286A1Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 3070US10702504B2Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Jul 7, 2020·1 cites·16 claims
- 3168US11293023B2Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 5, 2022·0 cites·13 claims
- 3255US10925868B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Feb 23, 2021·0 cites·19 claims
- 3354US2019127359A1Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin LigaseUNIV YALE·Filed 2018·Application pending·0 cites
- 3450US2022089589A1SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMSDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 3548US12023385B2Tunable endogenous protein degradation with heterobifunctional compoundsDANA FARBER CANCER INST INC·Filed 2018·Granted Jul 2, 2024·0 cites·24 claims
- 3647US2015119435A1Compounds useful for promoting protein degradation and methods using sameUNIV YALE·Filed 2013·Application pending·0 cites
- 3737US2020216454A1Bifunctional molecules for her3 degradation and methods of useDANA FARBER CANCER INST INC·Filed 2016·Application pending·0 cites
- 3837US2016022642A1Compounds Useful for Promoting Protein Degradation and Methods Using SameUNIV YALE·Filed 2015·Application pending·0 cites
- 3934US2016347750A1Dihydropteridinone derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Dennis Buckley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →